• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cocrystal Pharma Inc (NQ: COCP )

    1.730 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 1.730
    Bid (Size) 0.9500 (16)
    Ask (Size) 1.780 (120)
    Prev. Close 1.730
    Today's Range 1.730 - 1.730
    52wk Range 1.325 - 3.100
    Shares Outstanding 10,173,790
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Toll Brothers To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
    Via Benzinga
    CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event
    Via ACCESSWIRE

    Performance

    YTD
    -1.58%
    -1.58%
    1 Month
    +0.64%
    +0.64%
    3 Month
    -27.31%
    -27.31%
    6 Month
    +17.69%
    +17.69%
    1 Year
    -11.73%
    -11.73%

    More News

    Read More
    COCP Stock Earnings: Cocrystal Pharma Misses EPS for Q2 2024
    Via InvestorPlace
    COCP Stock Earnings: Cocrystal Pharma Beats EPS for Q1 2024
    Via InvestorPlace
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Recap: Cocrystal Pharma Q4 Earnings
    Via Benzinga
    Recap: Cocrystal Pharma Q3 Earnings
    Via Benzinga
    Analyst Ratings for Cocrystal Pharma
    Via Benzinga
    Why Cocrystal Pharma Shares Are Trading Higher Today
    Via Benzinga
    COCP Stock Earnings: Cocrystal Pharma Beats EPS for Q4 2023
    Via InvestorPlace
    Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    $2M Bet On Cocrystal Pharma? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
    Via Benzinga
    Why Tupperware Brands Shares Are Trading Lower By Over 40%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Why Pioneer Natural Resources Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Why eHealth Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast
    Via Newsfile
    Exposures COVID-19
    Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022
    From Cocrystal Pharma, Inc.
    Via GlobeNewswire
    Stocks That Hit 52-Week Lows On Friday
    Via Benzinga
    Cocrystal Pharma Posts Favorable Safety Data From Oral Antiviral Against Influenza A
    Via Benzinga
    Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A
    From Cocrystal Pharma, Inc.
    Via GlobeNewswire
    Cocrystal Pharma Reports Third Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
    From Cocrystal Pharma, Inc.
    Via GlobeNewswire
    Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.